Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Briacell Therapeutics Corp (BCT.VN)

Briacell Therapeutics Corp (BCT.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Briacell Therapeutics Corp 235 - 15th Street Suite 300, West Vancouver Vancouver BC V7T 2X1 CAN

P: 604-921-1810

Description:

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.

Key Statistics

Overview:

Market Capitalization, $K 168,676
Shares Outstanding, K 15,913
Annual Sales, $ 0 K
Annual Net Income, $ -428 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -2,386 K
60-Month Beta 1.44
% of Institutional Shareholders 0.28%

Growth:

1-Year Return 90.99%
3-Year Return -60.74%
5-Year Return -82.33%

Per-Share Information:

Latest Earnings Date 12/29/21
Earnings Per Share ttm 0.29
EPS Growth vs. Prev Year -97.08%
Dividend Payout Ratio 0.00%
Most Recent Split 1-300 on 01/02/20

BCT.VN Ratios

Ratio
Price/Earnings ttm 28.59
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -9.20%
Return-on-Assets % -8.46%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Book 2.38
Book Value/Share 4.45
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar